Holen Sie sich die Stockscreener-App
0.8719
5.51%
0.0519
Handel nachbörslich:
.90
0.0281
+3.22%
Schlusskurs vom Vortag:
$0.82
Offen:
$0.86
24-Stunden-Volumen:
109.68K
Relative Volume:
0.77
Marktkapitalisierung:
$31.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.21M
KGV:
-1.4925
EPS:
-0.5842
Netto-Cashflow:
-
1W Leistung:
+13.54%
1M Leistung:
+15.34%
6M Leistung:
-26.05%
1J Leistung:
-43.08%
1-Tages-Spanne:
$0.85
$0.8798
1-Wochen-Bereich:
$0.7603
$0.8765
52-Wochen-Spanne:
$0.63
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Firmenname
Neurosense Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare NRSN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.8719 | 29.60M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten
Amyotrophic Lateral Sclerosis (ALS) Market Set for Significant - openPR.com
NeuroSense Therapeutics (NRSN) Slides 4.56% as Support Levels Are TestedExpert Market Insights - Newser
TradingKey - TradingKey
NRSN (NeuroSense Therapeutics) Q2 loss narrows 6.9% more than expected, but investors await pipeline catalyst update.Expert Verified Trades - newser.com
NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price - The Globe and Mail
NeuroSense Announces Pricing of Insider-Led PIPE Financing - The Malaysian Reserve
NeuroSense (Nasdaq: NRSN) insiders lead $600K PIPE financing at premium - Stock Titan
NeuroSense Therapeutics Ltd. announced that it expects to receive $0.6 million in funding - marketscreener.com
Roth MKM Maintains NeuroSense Therapeutics(NRSN.US) With Buy Rating, Maintains Target Price $3 - Moomoo
NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones - The Globe and Mail
NeuroSense (NRSN) CMO steps down but stays on as advisor for PrimeC - Stock Titan
Niva Russek Blum Net Worth (2026) - GuruFocus
Ferenc Tracik Net Worth (2026) - GuruFocus
Hagit Binder Net Worth (2026) - GuruFocus
Alon Ben Noon Net Worth (2026) - GuruFocus
Revital Mandil Levin Net Worth (2026) - GuruFocus
Tangible book value per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
EBIT per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Operating cash flow per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
NEUROSENSE THERAPEUTICS LTD (NRSN) Earnings History & Surprises - ChartMill
Form 20-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)] - ADVFN
Sentiment Review: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesPortfolio Gains Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Nasdaq Moves: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingPortfolio Value Report & Real-Time Sentiment Analysis - baoquankhu1.vn
Patterns Watch: Is NeuroSense Therapeutics Ltd Equity Warrant part of any ETF2026 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
If You Invested $1,000 in Neurosense Therapeutics Ltd (NRSN) - Stock Titan
Trend Report: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingWeekly Risk Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Bank Watch: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingMarket Weekly Review & Daily Stock Trend Reports - baoquankhu1.vn
Chipmakers Recap: Why is NeuroSense Therapeutics Ltd stock going downEarnings Growth Summary & Weekly Market Pulse Alerts - baoquankhu1.vn
Aug Highlights: What are NeuroSense Therapeutics Ltd Equity Warrants earnings expectations2026 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn
NRSN Analyst Rating Update: D. Boral Capital Maintains 'Buy' Rat - GuruFocus
Inflation Data: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right nowEarnings Summary Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Volatility Watch: Can NeuroSense Therapeutics Ltd Equity Warrant keep up with sector leaders2026 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Breakout Watch: Is NeuroSense Therapeutics Ltd gaining market share2026 Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Income Plays: Is NeuroSense Therapeutics Ltd stock a value trap2026 AllTime Highs & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd stock a buy or sellMarket Trend Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn
NeuroSense granted Brazilian patent covering PrimeC composition - TipRanks
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements - marketscreener.com
NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC - TipRanks
NeuroSense Granted Brazilian Patent Covering PrimeC Composition - Bitget
Form 6-KReport of foreign issuer [Rules 13a-16 and 15d-16] - ADVFN
Brazil grants NeuroSense (NRSN) patent protecting PrimeC ALS and Alzheimer’s drug - Stock Titan
NeuroSense Therapeutics Faces Nasdaq Deficiency Notices but Retains Listing Status - The Globe and Mail
NRSN PE Ratio & Valuation, Is NRSN Overvalued - Intellectia AI
NeuroSense Therapeutics Ltd. (NRSN) stock price, news, quote and history - Yahoo Finance UK
NeuroSense Therapeutics Receives Nasdaq Notifications on Compliance Issues - National Today
NeuroSense Faces Nasdaq Compliance Warning - Intellectia AI
Nasdaq flags NeuroSense (NRSN) for bid price and $35M value shortfall - Stock Titan
NeuroSense Therapeutics Ltd. Stock Forecast Summary - Meyka
NeuroSense (NRSN) Stock: Slides After Nasdaq Compliance Warning on Price and Valuation - parameter.io
NRSN’s $1.00 Bid Price Requirement Serves as Key Trigger for Meeting Compliance and Raising Capital - Bitget
Finanzdaten der Neurosense Therapeutics Ltd-Aktie (NRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):